Protocol Ledger

NCT05193916 · Phase II · COMPLETED

A Phase II Clinical Trial of Chiglitazar for NASH

Interventional Phase II clinical trial protocol NCT05193916 sponsored by Chipscreen Biosciences in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-21 Enrollment: 104 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05193916
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)104 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05193916
Protocol FieldVerified Registry Value
NCT IdentifierNCT05193916
Consolidated Lead SponsorChipscreen Biosciences
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment104 participants (ACTUAL)
Registered Start Date2022-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI